Mr. Kenneth Howling reports

TRIMEL ANNOUNCES APPOINTMENT OF TOM ROSSI TO ITS BOARD OF DIRECTORS

Trimel Pharmaceuticals Corp. has appointed Tom Rossi, the company's president and chief executive officer, to its board of directors, effective Jan. 21, 2014.

Mr. Rossi joined Trimel in August, 2011, and was appointed president and chief executive officer in January, 2013. He has over 25 years experience in the pharmaceutical industry in Canada and abroad. He previously worked for Johnson & Johnson, Boehringer Mannheim, Merck & Co. and Novartis. As chief executive officer of Novartis Pharmaceuticals Canada Inc., Mr. Rossi led Canada's fourth-largest pharmaceutical company with annual sales in excess of $800-million and over 700 employees while delivering significant levels of profitability to the corporation. Mr. Rossi is a native of Montreal, where he graduated from McGill University, majoring in microbiology and immunology, and holds an MBA from Concordia University.

Ian Ihnatowycz, chair of the board of directors of Trimel, stated: "The board joins me in welcoming Tom as a director. His corporate knowledge, experience and leadership have been important in his continuing role as CEO, and will be vital as Trimel embarks on a new phase of growth and development."